107 related articles for article (PubMed ID: 16810714)
1. Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
Panhard X; Taburet AM; Piketti C; Mentré F
Stat Med; 2007 Mar; 26(6):1268-84. PubMed ID: 16810714
[TBL] [Abstract][Full Text] [Related]
2. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
Panhard X; Mentré F
Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916
[TBL] [Abstract][Full Text] [Related]
3. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
[TBL] [Abstract][Full Text] [Related]
4. BMS issues PK notice regarding ATV + TDF.
IAPAC Mon; 2003 Sep; 9(9):203. PubMed ID: 14672069
[No Abstract] [Full Text] [Related]
5. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
[TBL] [Abstract][Full Text] [Related]
6. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
7. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
Solas C; Gagnieu MC; Ravaux I; Drogoul MP; Lafeuillade A; Mokhtari S; Lacarelle B; Simon N
Ther Drug Monit; 2008 Dec; 30(6):670-3. PubMed ID: 18806695
[TBL] [Abstract][Full Text] [Related]
9. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
AIDS; 2007 Jul; 21(11):1431-9. PubMed ID: 17589189
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of tenofovir in AIDS patients.
Gagnieu MC; Barkil ME; Livrozet JM; Cotte L; Miailhes P; Boibieux A; Guitton J; Tod M
J Clin Pharmacol; 2008 Nov; 48(11):1282-8. PubMed ID: 18779377
[TBL] [Abstract][Full Text] [Related]
11. Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.
Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Fucile S; Clementi E
Fundam Clin Pharmacol; 2013 Apr; 27(2):216-22. PubMed ID: 22044510
[TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
13. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney BP; Mathias A
Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
[TBL] [Abstract][Full Text] [Related]
15. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Dumond JB; Nicol MR; Kendrick RN; Garonzik SM; Patterson KB; Cohen MS; Forrest A; Kashuba AD
Clin Pharmacokinet; 2012 Dec; 51(12):809-22. PubMed ID: 23044523
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
Calcagno A; Bonora S; Tettoni MC; D'Avolio A; Perri GD; Lanzafame M; Penco G
J Acquir Immune Defic Syndr; 2009 Nov; 52(3):431-2. PubMed ID: 19858926
[No Abstract] [Full Text] [Related]
20. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
